Etoposide, an important anticancer agent, undergoes glucuronidation both in vitro and in vivo. In this study, three isomeric glucuronides of etoposide, including one phenolic (EPG) and two alcoholic glucuronides (EAG1 and EAG2), were biosynthesized in vitro with human liver microsomes (HLMs), and identified by liquid chromatography-electrospray ionization-mass spectrometry and confirmed by 
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Introduction
Glucuronidation represents a major conjugative reaction catalyzed by UDP-glucuronosyltransferases (UGTs). To date, 18 human UGT isoforms, including UGT1A1, 1A3, 1A4, 1A5, 1A6, 1A7, 1A8, 1A9, 1A10, 2A1, 2A2, 2B4, 2B7, 2B10, 2B11, 2B15, 2B17 and 2B28, have been identified (Mackenzie, et al., 1997; Finel, et al., 2005) . Most of UGT enzymes are expressed in the liver, whereas UGT1A7, 1A8 and 1A10 are reported to be exclusively expressed in extrahepatic tissues (Radominska-Pandya, et al., 1999; Tukey and Strassburg, 2000; King, et al., 2000; Ritter, 2000) . Human UGTs generally exhibit distinct but overlapping substrate specificities, and most substrates are glucuronidated by multiple UGT isoforms (Radominska-Pandya, et al., 1999; Tukey and Strassburg, 2000; King, et al., 2000; Ritter, 2000; Fisher, et al., 2001 ). Identification of human UGTs responsible for the glucuronidation of existing and novel drugs provides critical information about potential drug-drug interactions (Kiang, et al., 2005) . Unlike cytochrome P450-mediated biotransformation, UGT reaction phenotyping has attracted less attention.
Reasons for this include the limited availability of isoform-selective UGT substrates or antibodies and the relatively low incidence of drug-drug interactions involving UGT-catalyzed reactions in vivo (Williams, et al., 2004; Miners, et al., 2006) . Several compounds, including bilirubin (Bosma, et al., 1994) , β -estradiol
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8 Gentest (Woburn, MA). Pooled human liver microsomes (HLMs) were obtained from In Vitro
Technologies (Baltimore, MD). Pooled human intestinal microsomes (HIMs) were purchased from XenoTech (Lenexa, Kansas). The protein contents of HLMs, HIMs and recombinant human UGTs were used as described in the data sheets provided by the manufacturers. Enzyme activities of recombinant human UGTs, HLMs and HIMs were confirmed by HPLC-UV assays as described by the manufacturers with modifications, using 7-hydroxy-4-trifluoromethylcoumarin as a substrate for 11 UGT isoforms (except UGT1A4), HLMs and HIMs, and trifluoperazine as a substrate for UGT1A4. Acetonitrile (ACN;
HPLC grade) was obtained from Mallinckrodt (Phillipsburg, NJ). All other chemicals and reagents were of analytical grade. were preincubated on ice for 10 min. After the addition of MgCl 2 (10 mM), D-SL (10 mM) and etoposide, the incubation mixture was preincubated at 37ºC for 5 min. The reaction was initiated by the addition of UDPGA (2 mM) and incubated at 37ºC in a shaking water bath for 30 min. The reaction was terminated by the addition of 800 µ l of ice-cold ACN containing internal standard AZT (6.25 µ g). After the removal of protein by centrifugation at 15,000g for 10 min at 4ºC, the supernatants were transferred and dried with a stream of nitrogen at 45ºC in a water bath. The residue was reconstituted in 125 µl of ACN/0.1% formic acid (20:80, v/v Biosynthesis of Etoposide Glucuronides. Enzymatic biosynthesis of EGs was conducted using HLMs.
Glucuronidation of Etoposide. In vitro glucuronidation of etoposide was conducted in an incubation
Briefly, 1 mM of etoposide was incubated with HLMs (2 mg protein/ml), 0.1 M Tris-HCl (pH 7.4), MgCl 2 (10 mM), Brij 35 (0.5 mg/mg protein), D-SL (10 mM) and UDPGA (2 mM) in 2×10 ml of final incubations for 7 h at 37ºC. The stock solution of etoposide (0.5 M) was prepared in DMSO/MeOH (50:50, v/v) . The concentration of organic solvent in the final incubation was 0.2%. The reaction was terminated by the addition of 2×30 ml of ice-cold ACN. After the removal of protein by centrifugation at 15,000g for 15 min at 4ºC, the supernatants were pooled and dried with a stream of nitrogen at 45ºC. The residue was reconstituted in 3 ml of ACN/1% acetic acid (20:80, v/v) and stored at -20ºC until use.
Separation of EGs was performed by a preparative HPLC method using an Econosil C18 column This article has not been copyedited and formatted. The final version may differ from this version. Chicago, IL). The apparent kinetic parameters were reported as mean ± standard error (SE) from individual duplicates.
Inhibitory Effects of Typical Probe Substrates on Etoposide UGT Activity in HLMs.
Bilirubin (Bosma, et al., 1994) , β -estradiol (Senafi et al., 1994; Soars, et al., 2003) (Fenselau and Johnson, 1980; Niemeijer, et al., 1991) , the MS spectra of EAG1 and EAG2 were very similar and did exhibit the deprotonated glucuronic acid ion (m/z 193), whereas EPG did not. These different in-source MS fragmentation pathways of glucuronic acid moieties in etoposide phenolic and alcoholic glucuronides in the negative ion mode (Fig. 6 ) were in agreement with previous findings about phenolic and alcoholic glucuronides (Niemeijer, et al., 1991; Gu, et al., 1999; Levsen, et al., 2005) . Additional evidence for the identification of the positional isomers of phenolic and alcoholic glucuronides is their different chromatographic retentions on reversed-phase HPLC, as phenolic glucuronides (e.g., EPG, t R = 8.0 min) are generally more hydrophilic, and consequently have earlier elution than those of alcoholic glucuronides (e.g., EAG1 and EAG2, t R = 9.0 and 9.5 min, respectively).
The similar examples include estradiol 3-and 17-glucuronides (Alkharfy and Frye, 2002) , ethinylestradiol 3-and 17-glucuronides (Ebner, et al., 1993) , and the phenolic and alcoholic glucuronides of denopamine (Kaji and Kume, 2005) and labetalol (Niemeijer, et al., 1991) . However, the conjugation sites of the two alcoholic glucuronides of etoposide could not be individually identified by MS methods, and this need to be further elucidated. In addition, in this study, the formation of di-or tri-glucuronides of etoposide was not observed under the experimental conditions. This article has not been copyedited and formatted. The final version may differ from this version. Quantification of EGs was then performed with SIM detection in the negative ionization mode. The limit of detection was 0.5 ng/ml for all forms of EGs with injection volume of 20 µl. The quantitative linear ranges were 2 to 1500 ng/ml for EPG, and 1 to 1000 ng/ml for EAG1 and EAG2. The intra-day precisions (relative standard deviation, n = 4) were 1.5-5.6%, 1.0-6.4% and 1.1-7.0% for EPG, EAG1 and EAG2, respectively. The inter-day precisions (relative standard deviation, n = 4) were 1.5-6.8%, 1.2-4.0% for and 2.9-13% for EPG, EAG1 and EAG2, respectively. Experimentally, the most important MS parameters for the quantification of intact glucuronides were the cone voltages, including orifice and focusing ring Alcoholic glucuronides (EAG1 and EAG2) were the minor metabolites, with approximately 8-10%
glucuronidation rate of EPG formation (Figs. 2 and 7) . Among the three UGT isoforms that catalyzed the glucuronidation of etoposide, UGT1A1 had the highest glucuronide formation rates (62, 7.1 and 6.9
pmol/min/mg protein for EPG, EAG1 and EAG2, respectively). The activities of UGT1A8 (6.1, 0.37 and 3.7 pmol/min/mg protein for EPG, EAG1 and EAG2, respectively) and UGT1A3 (0.60, 0.64 and 0.05 pmol/min/mg protein for EPG, EAG1 and EAG2, respectively) were much lower than those of UGT1A1.
Enzyme Kinetic Parameters. Apparent enzyme kinetic parameters were estimated using various 
Discussion
Human UGTs generally exhibit distinct but overlapping substrate specificities, and most substrates are glucuronidated by more than one isoform (Radominska-Pandya, et al., 1999; Tukey and Strassburg, 2000; King, et al., 2000; Ritter, 2000; Fisher, et al., 2001 ). Due to the lack of specific antibodies for human UGT isoforms, it is important to alternatively explore some selective substrates for the evaluation of the responsibility of individual UGT isoforms. Currently, several compounds, including bilirubin (Bosma, et al., 1994) , β -estradiol (Senafi et al., 1994) and 17α-ethynylestradiol (Ebner et al., 1993) , have been used as the probe substrates for UGT1A1 in vitro. Bilirubin is putatively considered as the most specific substrate for UGT1A1 (Bosma, et al., 1994; Burchell, et al., 1995; King, et al., 2000) . However, simultaneous and accurate determination of bilirubin and its multiple glucuronidation isomers (including one di-glucuronide, and 2 cis/trans and 2 positional isomers of mono-glucuronides) is difficult due to the light sensitivity of bilirubin, and the instability or interconversion of mono-and di-glucuronide of bilirubin in vitro and in vivo (Jansen, et al., 1977; Chowdhury, et al., 1981; Gordon, et al., 1984; Miners, et al., 2004; Zhang, et al., 2005) . In addition, it has been reported that bilirubin may also inhibit UGT1A4 (Ghosal, et al., 2004) .
UGT1A1 predominantly catalyzes the phenolic glucuronidation of β -estradiol (Senafi et al., 1994; Soars, et al., 2003) at the position 3 with atypical kinetics, whereas UGT2B7 mainly catalyzes the alcoholic glucuronidation of β -estradiol at the position 17 (Gall, et al., 1999) . However, UGT1A8, 1A10 and 1A3
have been also reported to catalyze the glucuronidation of β -estradiol-3 with significant activities (Soars, et al., 2004) , while UGT1A3, 1A4, 1A8, 1A10 and 2B7 may also be involved in the glucuronidation of This article has not been copyedited and formatted. The final version may differ from this version. -estradiol-17 (Soars, et al., 2004) . Although 17α-ethinylestradiol glucuronidation is primarily catalyzed by UGT1A1 (Ebner et al., 1993) , other UGT isoforms (e.g., UGT1A4, 1A8 and 1A10) may also metabolize the glucuronidation of 17α-ethinylestradiol at lower but significant activities (Cheng, et al., 1999; King, et al., 2000; Tukey and Strassburg, 2000) . This overlapping substrate specificity for "probes"
of UGT1A1 complicates the interpretation of in vitro data, particularly in human intestinal tissues where relatively high levels of UGT 1A8 and 1A10 are expressed (Cheng, et al., 1999; Radominska-Pandya, et al., 1999; Tukey and Strassburg, 2000) . Since multiple UGT enzymes catalyze the glucuronidation of β -estradiol and 17α-ethinylestradiol, caution should be taken when these two compounds are chosen as the probe substrates of UGT1A1.
It has been recently reported that UGT1A1 only catalyzes the alcoholic glucuronidation of etoposide (Watanabe, et al., 2003) , but the glucuronidation pathways of etoposide were still unclear, considering its potential multiple glucuronidation products (Fig. 1) . Additionally, since etoposide glucuronide standards were not utilized, true Michaelis-Menten parameters were not determined. In this study, we reported that three positional isomeric glucuronides of etoposide (Fig. 2) , including one phenolic (EPG) and two alcoholic glucuronides (EAG1 and EAG2), were formed in the incubations containing recombinant human UGTs (UGT1A1, 1A3 and 1A8), HLMs and HIMs in vitro (Fig. 7) . The main glucuronidation product of etoposide was the phenolic glucuronide (EPG), whereas the two alcoholic glucuronides (EAG1 and EAG2) were the minor metabolites. The formation of multiple etoposide glucuronides in vitro found in this study is consistent with the previous in vivo results observed in rats and rabbits after administration This article has not been copyedited and formatted. The final version may differ from this version. of etoposide (Colombo, et al., 1985; Hande, et al., 1988a) , although the structures of etoposide glucuronides were not completely characterized in the previous publications. In this report, the structures of etoposide glucuronides were preliminarily identified by LC-ESI-MS both in the positive and negative ionization modes, and confirmed by β -glucuronidase cleavage, although the conjugation sites of the two alcoholic glucuronides of etoposide need to be further distinguished. Our data also indicated that, at the same concentrations, etoposide and its three glucuronides had different MS responses (EAG2 > EPG > EAG1 > etoposide), when measured in the negative ionization mode. Therefore, accurate quantification of etoposide glucuronides using the biosynthesized standards is necessary. UGT reaction screening (Fig. 7) and enzyme kinetic study (Figs. 8 and 9, and Tables 1 and 2) indicated that three UGT isoforms, including UGT1A1, 1A3 and 1A8, were responsible for the formation of etoposide glucuronides in vitro. UGT1A1
is the principal enzyme catalyzing etoposide glucuronidation, whereas the enzyme activities of UGT1A3 and 1A8 were only 1 and 10% of UGT1A1, respectively, although the individual contribution of the related UGT isoforms needs to be further confirmed and quantitatively compared considering the expressed levels among the different isoforms. The Eadie-Hofstee plots for HLMs and HIMs (Fig. 8D , E, and F) showed the involvement of a single UGT isoform, UGT1A1, in the etoposide glucuronidation reactions, suggesting the contributions of UGT1A8 or 1A3 might be minor. In addition, inhibitory study also indicated that etoposide is the selective substrate of bilirubin glucuronidating isoform, UGT1A1 ( Fig.   10 and Table 3 ).
In conclusion, we demonstrated that three isomeric glucuronides of etoposide were formed in vitro, This article has not been copyedited and formatted. The final version may differ from this version. 
